DESTINY PHARMACEUTICALS - A Biotech Company for the Age of Infectious Diseases

DESTINY PHARMACEUTICALS - A Biotech Company for the Age of Infectious Diseases

Isaac Hastings
Biotechnology, Pharmaceuticals

Destiny Pharma is a clinical stage, biotechnology company focused on the development of novel medicines for the treatment of infectious diseases. The Company aims to develop new drugs for the prevention and treatment of life-threatening infections caused by antibiotic resistant bacteria, popularly referred to as superbugs. The need to develop medicines that combat antimicrobial resistant bacteria (AMR) is a medical priority highlighted by authorities including the FDA and the WHO.

Gauging the outcome of clinical trials requires the prospective investor to consider not just the clinical research done to this point, but to also assess the individuals responsible for developing the product and company. The purpose of this report is to present the facts of the matter in an objective manner to aid the reader in deriving their own informed judgement on Destiny Pharma’s prospects.

LEARNING TECHNOLOGIES GROUP: a specialist tech plc and growth by acquisition

LEARNING TECHNOLOGIES GROUP: a specialist tech plc and growth by acquisition

Isaac Hastings
Technology

Learning Technologies Group PLC is listed on AIM as LON:LTG.  The company operates in the technology sector specialising in E-learning technologies.    

Historically, investors have not always reacted to positive interim and final results.  There will be several factors to this, high among the list being LTG is still relatively new to AIM investors.  After two solid financial reports and regular news-making acquisitions, LTG may well now be on investors’ radar.  The 10% share price bounce after the last Interim Results in September 2016 certainly seems to suggest as much.

ANGUS ENERGY: small exploration plc, big production ambitions

ANGUS ENERGY: small exploration plc, big production ambitions

Isaac Hastings
Energy

ANGS has survived the historic low levels of Brent crude and the market wobbles in the aftermath of the EU Referendum.  While there will be turbulence in the future, it seems Angus Energy has an ability to weather most storms. There is also the prospect of brighter news further ahead as the UK government may soon be able to provide fiscal and legislative support to the onshore industry.  And of course, we will soon find out whether Brockham can actually deliver 1500 bopd, a flow rate twelve times greater than the Xodus estimate of 127 bopd for the oilfield.

VERNALIS: AIM-listed pharma co looking to make it big in the US

VERNALIS: AIM-listed pharma co looking to make it big in the US

Isaac Hastings
Pharmaceuticals

In the short to medium term Vernalis may seem a value buy especially with brokers lining up with "Buy" ratings. The wisdom may be questionable given the share price slumped 20% when poor interim results were announced. There are opportunities for good news: CCP-07 & 08 could both be FDA approved by June 2017 and potential for more milestone payment announcements. June's expected Tuzistra sales update is a potential and serious banana peel. It will also act as an early indication of Final Results due to be announced in September 2017.